| Cat.No. | Name | Information |
|---|---|---|
| M54529 | IDH1 Inhibitor 8 | IDH1 Inhibitor 8 is an isocitrate dehydrogenase 1 (IDH1) inhibitor that can be used in cancer-related studies. |
| M14456 | Mutant IDH1 inhibitor | Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM. |
| M14454 | Mutant IDH1-IN-1 | Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively. |
| M14453 | Enasidenib mesylate | Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes. |
| M11277 | IDH889 | IDH889 is an orally available, brain permeable, allosteric and mutation-specific inhibitor of isocitrate dehydrogenase (IDH1). IDH889 showed high selectivity against IDH1R132 * mutant, with IC50 values of 0.02 μM, 0.072 μM and 1.38 μM against IDH1R132H, IDH1R132C and IDH1wt, respectively. IDH889 showed high inhibition of intracellular 2-Hg level with IC50 value of 0.014 μM. |
| M10434 | Olutasidenib (FT-2102) | Olutasidenib (FT-2102) is a highly potent and selective, orally active, brain penetrant mutant Isocitrate dehydrogenase 1 (IDH1) inhibitor, with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively. |
| M10335 | IDH-305 | IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1(R132) mutation with IC50 values of 27 nM, 28 nM and 6.14 μM for IDH1R132H, IDH1R132C and IDH1WT, respectively. |
| M10308 | Vorasidenib | Vorasidenib (AG-881) is a potent and selective, first-in-Class, brain-penetrant orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria. |
| M9533 | DS-1001b (Safusidenib t-Butylamine) | DS-1001b (Safusidenib t-Butylamine) is a potent, orally bioavailable, selective mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor with antitumor activity. |
| M8958 | Ivosidenib | Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. |
| M8651 | GSK864 | GSK864 is a cell penetrant, potent and selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) that potently inhibits intracellular 2-hydroxyglutarate (2-HG) production in HT-1080 cells. |
| M6212 | BAY-1436032 | BAY1436032 is a novel pan-mutant IDH1 inhibitor, it specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells. |
| M4945 | Enasidenib | Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2R140Q and IDH2R172K, respectively. |
| M2371 | AGI-6780 | AGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM. |
| M2067 | AGI-5198 | AGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H and R132C mutants in vitro with IC50 values of 0.07 μM and 0.16 μM, respectively. |
| M54537 | Mutant IDH1-IN-4 | Mutant IDH1-IN-4 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH 1) with an IC50 value of ≤ 0.5 μM for mutant IDH 1 in R132H, HT1080 and U87R132H cells. |
| M54536 | (S,S)-GSK321 | (S,S)-GSK321 is the (S,S)-enantiomer of GSK321.GSK321 is a potent inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme. |
| M54535 | IDH1 Inhibitor 1 | IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-permeable, selective mutant IDH1 inhibitor that inhibits IDH1R132H, IDH1R132C, and IDH1WT with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM, respectively. possesses antitumor activity. |
| M54534 | IDH1 Inhibitor 7 | IDH1 Inhibitor 7 is an IDH1 inhibitor with an IC50 of less than 100 nM. |
| M54533 | (R,R)-GSK321 | (R,R)-GSK321 is an isomer of GSK321 and a wild-type isocitrate dehydrogenase 1 (WT IDH1) inhibitor with an IC50 value of 120 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
